Contact our breast care nurses 0808 800 6000

Breast Cancer Now media statements

103 results
Media Statement
Response to the announcement of a new Major Conditions Strategy

Responding to today’s Government announcement of a new ‘Major Conditions Strategy’, Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, said:

25 Jan 2023

Media Statement
Breast Cancer Now responds to December's NHSE Waiting Times Data

Responding to the latest NHSE Cancer Waiting Times Data, Melanie Sturtevant, Associate Director for Policy, Evidence and Influencing at Breast Cancer Now, said: 

17 Jan 2023

Media Statement
We respond to the launch of the first UK proton beam therapy trial for breast cancer patients

Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, has commented on the launch of the first UK proton beam therapy trial for breast cancer patients.

03 Jan 2023

Media Statement
We respond to new estimates that 57,215 people were living with secondary (metastatic) breast cancer in England in 2020 to 2021

Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, has commented on the new estimates.

22 Dec 2022

Media Statement
We respond to NICE’s approval of trastuzumab deruxtecan (Enhertu) for use on the Cancer Drugs Fund

Chief Executive of Breast Cancer Now, Baroness Delyth Morgan, has commented on NICE'S decision to approve trastuzumab deruxtecan for use on the Cancer Drugs Fund.

20 Dec 2022

Media Statement
We respond to double SMC drug announcement - adjuvant abemaciclib and alpelisib with fulvestrant

Chief Executive of Breast Cancer Now, Baroness Delyth Morgan, has commented on the double announcement by the Scottish Medicines Consortium.

12 Dec 2022

Media Statement
We respond to research about a potential new treatment for advanced breast cancer patients

Dr Kotryna Temcinaite, our senior research communications manager, commented on research presented at the 2022 San Antonio Breast Cancer Symposium, which showed the benefits of the drug capivasertib alongside hormone therapy for patients with advanced breast cancer.

08 Dec 2022

Media Statement
We respond to research about radiotherapy and long-term breast cancer survival

Dr Kotryna Temcinaite, our Senior Research Communications Manager, has responded to research presented at the 13th European Breast Cancer Conference about radiotherapy and long-term survival.

18 Nov 2022

Media Statement
We respond to research about the benefits of exercise

Dr Kotryna Temcinaite, our Senior Research Communications Manager, has commented on research published in JAMA Open Network about the benefits of exercise for women recovering from breast cancer.

18 Nov 2022

Media Statement
We respond to research about women with benign breast disease being at higher risk of breast cancer in the long term

Dr Kotryna Temcinaite, our Senior Research Communications Manager, has commented on research presented at the 13th European Breast Cancer Conference. This research showed that women who have benign breast conditions, including cysts and fibroadenomas, have a higher risk of developing breast cancer in the long term.

17 Nov 2022

Media Statement
We respond to latest NHSE Cancer Wait Times data

Melanie Sturtevant, Associate Director for Policy, Evidence and Influencing at Breast Cancer Now, has commented on the latest NHS England Cancer Wait Times data.

11 Nov 2022

Media Statement
We respond to NICE’s devastating decision to provisionally reject the use of olaparib on the NHS

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said NICE’s decision to provisionally reject the use of olaparib on the NHS was "devastating".

10 Nov 2022